Global Autoimmune Polyglandular Syndrome Type 1 Market Poised for Steady Growth Due to Increasing Incidence of Autoimmune Disorders
![]() |
Global Autoimmune Polyglandular Syndrome Type 1 Market |
Autoimmune
polyglandular syndrome type 1 (APS1) is a rare, genetic autoimmune disorder
that affects multiple endocrine glands. It is characterized by chronic
mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. The
symptoms arise due to loss of function in specific glands such as parathyroid,
adrenal and gonadal glands. APS1 requires lifelong management through hormone
replacement and immunotherapy. The global APS1 market comprises products such
as immunosuppressants, hormone replacement therapies, antifungal drugs, and
vaccines. The market is driven by the increasing incidence of autoimmune
disorders as a result of genetic and environmental factors. The Global
Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at
US$ 257.0 MN in 2024 and is expected to exhibit a CAGR of 3.1% over the
forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Global Autoimmune Polyglandular Syndrome Type 1
Market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva
Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus
Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma,
Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical
Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical
Company Limited, Abbott, and LEO Pharma A/S.
The key opportunities in the market include development of novel therapies
targeting underlying autoimmunity and development of preventive vaccines.
Geographically, North America dominates the market currently. However, Asia
Pacific is expected to witness highest growth owing to improving healthcare
infrastructure and increasingmedical expenses over the forecast period.
Europe is also expected to offer lucrative growth opportunities during the
forecast period due to high incidence of APS1 and related autoimmune disorders.
Moreover, growing awareness regarding early diagnosis and treatment adherence
is driving the market globally.
Market Drivers and Restraints
The increasing incidence of autoimmune disorders due to rising environmental
pollution and genetic predisposition are driving the APS1 market. Additionally,
growing geriatric population who are more prone to developing autoimmune
conditions acts as a growth driver. Also, increasing healthcare expenditures in
developing nations and demand for effective drugs for long-term management of
autoimmunity fuels the market growth.
However, lack of approved drugs for prevention and lack of understanding of
precise etiology of APS1 are some of the major challenges in the market.
Additionally, stringent regulatory framework for drugs approval acts as a
market restraint. High treatment costs associated also impedes the market
growth to some extent.
Segment
Analysis
The Global
Autoimmune Polyglandular Syndrome Type 1 Market can be segmented on the
basis of disease type and end user. By disease type, Addison's disease
dominates the market owing to high prevalence of this condition among
Autoimmune Polyglandular Syndrome Type 1 patients. Addison's disease occurs
when the body produces insufficient amounts of cortisol and aldosterone and is
a life-threatening condition requiring timely management. By end user,
hospitals hold a significant share due to availability of advanced treatment
facilities and skilled healthcare professionals for taking care of such
multi-system disorder patients. Outpatient care centers are expected to witness
faster growth during the forecast period.
Global Analysis
Regionally, North America is expected to account for the largest share in the
global Autoimmune Polyglandular Syndrome Type 1 market due to high awareness
levels, availability of advanced treatments and favorable reimbursement
policies in countries like United States and Canada. Asia Pacific is
anticipated to grow at the fastest rate during the forecast period driven by
rapidly developing healthcare infrastructure, rising healthcare expenditure and
increasing treatment seeking rate in developing countries like India and China.
On the basis of treatments, immunosuppressive drug therapies hold the dominant
market share as they help prevent the destruction of glands by autoimmune
cells. But gene therapies are poised to offer lucrative opportunities in the
coming years.
For more details on the report, Read- https://www.rapidwebwire.com/global-autoimmune-polyglandular-syndrome-type-1-market-growth/
Comments
Post a Comment